Navigation Links
Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment

RYE, N.Y., Oct. 14 /PRNewswire/ -- Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced that it has enrolled the first patients in Phase III clinical trials for its autism treatment, CM-AT. The first clinical trial patients have been enrolled at Lake Mary Pediatrics in Orange City, Florida, one of 12 clinical trial sites with a total 170 children across the country.

CM-AT is based on research by Curemark founder and CEO Dr. Joan Fallon that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein. The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function.

"We are very excited to be enrolling our first children in the Phase III trials for CM-AT. Our progress with the clinical trials culminates years of research resulting in the breakthrough discovery of this therapy for children with autism," Fallon said. "We're hopeful that CM-AT will be one of the first therapies to address the underlying physiology of autism, rather than just treat its symptoms."

A new study released in early October by the U.S. Centers for Disease Control (CDC) showed that the number of children affected by autism is much higher than originally thought. According to the study, autism affects 1 in 91 children and about 1 in 58 boys, totaling an estimated 673,000 or approximately 1% of all children in the U.S.

For information on participating in the trials, log on to and search "Curemark."


Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.

SOURCE Curemark, LLC

SOURCE Curemark, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Appoints Preeminent Pediatrics Gastroenterologist
2. Curemark Closes Series A Financing
3. Curemark CEO Presents at Epigenomics Conference
4. Curemark Announces Senior Executive Promotions
5. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
6. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
7. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
8. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
9. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
10. Transdel Enrolls First Patient for Ketotransdel(TM) Phase 3 Clinical Trial
11. Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial
Post Your Comments:
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/22/2017)... SAN DIEGO , Sept. 22, 2017 ... ll medical device is now successfully helping those with ... Union. Fibromyalgia diagnosed Amanda in ... getting dressed and washing my hair, experiencing no sleep ... body in painful spasm… I cannot recommend [the AVACEN ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... ProVest Insurance Group, a family managed ... Raleigh regions, is organizing an extended charity drive to benefit the family of ... , After struggling since birth with several health challenges, T.J. was later diagnosed ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... As health ... medicine known as “patient engagement.” The patient is doing more than filling out a ... , “There is an increasing emphasis in health care and research on the ...
(Date:10/13/2017)... LEXINGTON, Ky. (PRWEB) , ... October 13, 2017 , ... ... MD, MPH to become its next President and Chief Executive Officer, succeeding Dr. James ... and CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end ...
(Date:10/13/2017)... ... , ... PurhealthRX , a leading Health and Nutrition Company, is announcing ... full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the ... incorporated into liquid products, while reducing costs to end users. , The team of ...
(Date:10/13/2017)... QUEENS, N.Y (PRWEB) , ... October 13, 2017 , ... ... recently became a member of ElderCounsel, a national organization of elder law and special ... constantly changing laws and rules. It also provides a forum to network with elder ...
Breaking Medicine News(10 mins):